Cabezón Itsaso, Manich Gemma, Martín-Venegas Raquel, Camins Antoni, Pelegrí Carme, Vilaplana Jordi
Departament de Fisiologia, Facultat de Farmàcia, Universitat de Barcelona , 08028 Barcelona, Spain.
Unitat de Farmacologia i Farmacognòsia, Facultat de Farmàcia, Universitat de Barcelona , 08028 Barcelona, Spain.
Mol Pharm. 2015 Nov 2;12(11):4137-45. doi: 10.1021/acs.molpharmaceut.5b00597. Epub 2015 Oct 15.
Receptor-mediated transcytosis has been widely studied as a possible strategy to transport neurotherapeutics across the blood-brain barrier (BBB). Monoclonal antibodies directed against the transferrin receptor (TfR) have been proposed as potential carrier candidates. A better understanding of the mechanisms involved in their cellular uptake and intracellular trafficking is required and could critically contribute to the improvement of delivery methods. Accordingly, we studied here the trafficking of gold nanoparticles (AuNPs) coated with the 8D3 anti-transferrin receptor antibody at the mouse BBB. 8D3-AuNPs were intravenously administered to mice and allowed to recirculate for a range of times, from 10 min to 24 h, before brain extraction and analysis by transmission electron microscope techniques. Our results indicated a TfR-mediated and clathrin-dependent internalization process by which 8D3-AuNPs internalize individually in vesicles. These vesicles then follow at least two different routes. On one hand, most vesicles enter intracellular processes of vesicular fusion and rearrangement in which the AuNPs end up accumulating in late endosomes, multivesicular bodies or lysosomes, which present a high AuNP content. On the other hand, a small percentage of the vesicles follow a different route in which they fuse with the abluminal membrane and open to the basal membrane. In these cases, the 8D3-AuNPs remain attached to the abluminal membrane, which suggests an endosomal escape, but not dissociation from TfR. Altogether, although receptor-mediated transport continues to be one of the most promising strategies to overcome the BBB, different optimization approaches need to be developed for efficient drug delivery.
受体介导的转胞吞作用作为一种将神经治疗药物转运穿过血脑屏障(BBB)的可能策略已得到广泛研究。针对转铁蛋白受体(TfR)的单克隆抗体已被提议作为潜在的载体候选物。需要更好地理解其细胞摄取和细胞内运输所涉及的机制,这可能对改善递送方法至关重要。因此,我们在此研究了用8D3抗转铁蛋白受体抗体包被的金纳米颗粒(AuNPs)在小鼠血脑屏障处的运输情况。将8D3-AuNPs静脉注射给小鼠,并使其循环一定时间,从10分钟到24小时,然后进行脑提取并通过透射电子显微镜技术进行分析。我们的结果表明存在一种TfR介导且依赖网格蛋白的内化过程,通过该过程8D3-AuNPs分别在囊泡中内化。这些囊泡随后至少遵循两条不同的途径。一方面,大多数囊泡进入囊泡融合和重排的细胞内过程,其中AuNPs最终积聚在晚期内体、多囊泡体或溶酶体中,这些结构中AuNP含量很高。另一方面,一小部分囊泡遵循不同的途径,它们与管腔内膜融合并向基底膜开放。在这些情况下,8D3-AuNPs仍附着在管腔内膜上,这表明存在内体逃逸,但并非与TfR解离。总之,尽管受体介导的运输仍然是克服血脑屏障最有前景的策略之一,但需要开发不同的优化方法以实现高效的药物递送。